Delving into the Latest Updates on Nonpeptide cyclic ureas(DuPont Merck Pharmaceutical) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

HIV-1 protease

Action

inhibitors

Mechanism

HIV-1 protease inhibitors(Human immunodeficiency virus type 1 protease inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication-

Originator Organization

DuPont Merck Pharmaceutical Co.

Active Organization

DuPont Merck Pharmaceutical Co.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Jackson, David A. ; Otto, Michael J. ; Chang, Chong-Hwan ; Meek, James L. ; Rayner, Marlene M. ; Jadhav, Prabhakar K. ; Eyermann, Charles J. ; Hodge, C. Nicholas ; Ru, Yu ; Erickson-Viitanen, Susan ; Sharpe, Thomas R. ; Bacheler, Lee T. ; Lam, Patrick Y. S. ; Wong, Y. Nancy ; Weber, Patricia C.

Mechanistic information and structure-based design methods have been used to design a series of nonpeptide cyclic ureas that are potent inhibitors of human immunodeficiency virus (HIV) protease and HIV replication. A fundamental feature of these inhibitors is the cyclic urea carbonyl oxygen that mimics the hydrogen-bonding features of a key structural water molecule. The success of the design in both displacing and mimicking the structural water molecule was confirmed by x-ray crystallographic studies. Highly selective, preorganized inhibitors with relatively low molecular weight and high oral bioavailability were synthesized.

100 Deals associated with Nonpeptide cyclic ureas(DuPont Merck Pharmaceutical)

Login to view more data